July 9, 2025
| This week’s commercialization news and insights for biopharma leaders
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
|
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.
|
While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.
|
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.
|
UPDATED
The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people and healthy children were unlawful.
|
Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.
|
From Our Library
Webinar - on demand
Custom content for MMIT
|
Trendline
Supported by Premier Inc
|
View all resources
What We're Reading
ProPublica
|
Endpoints
|
Bloomberg
|
|